These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

210 related items for PubMed ID: 36328145

  • 1. IL2RA+VSIG4+ tumor-associated macrophage is a key subpopulation of the immunosuppressive microenvironment in anaplastic thyroid cancer.
    Pan Z, Bao L, Lu X, Hu X, Li L, Chen J, Jin T, Zhang Y, Tan Z, Huang P, Ge M.
    Biochim Biophys Acta Mol Basis Dis; 2023 Jan 01; 1869(1):166591. PubMed ID: 36328145
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Targeting SIGLEC15 as an emerging immunotherapy for anaplastic thyroid cancer.
    Bao L, Li Y, Hu X, Gong Y, Chen J, Huang P, Tan Z, Ge M, Pan Z.
    Int Immunopharmacol; 2024 May 30; 133():112102. PubMed ID: 38652971
    [Abstract] [Full Text] [Related]

  • 4. Integrative single-cell transcriptome analysis reveals immune suppressive landscape in the anaplastic thyroid cancer.
    Feng C, Tao Y, Yu C, Wang L, Liu X, Cao Y.
    Cancer Gene Ther; 2023 Dec 30; 30(12):1598-1609. PubMed ID: 37679527
    [Abstract] [Full Text] [Related]

  • 5. VSIG4 induces the immunosuppressive microenvironment by promoting the infiltration of M2 macrophage and Tregs in clear cell renal cell carcinoma.
    Zheng X, Tong T, Duan L, Ma Y, Lan Y, Shao Y, Liu H, Chen W, Yang T, Yang L.
    Int Immunopharmacol; 2024 Dec 05; 142(Pt A):113105. PubMed ID: 39260310
    [Abstract] [Full Text] [Related]

  • 6. Targeting CD47 in Anaplastic Thyroid Carcinoma Enhances Tumor Phagocytosis by Macrophages and Is a Promising Therapeutic Strategy.
    Schürch CM, Roelli MA, Forster S, Wasmer MH, Brühl F, Maire RS, Di Pancrazio S, Ruepp MD, Giger R, Perren A, Schmitt AM, Krebs P, Charles RP, Dettmer MS.
    Thyroid; 2019 Jul 05; 29(7):979-992. PubMed ID: 30938231
    [Abstract] [Full Text] [Related]

  • 7. Disruption of Cell-Cell Communication in Anaplastic Thyroid Cancer as an Immunotherapeutic Opportunity.
    Chakraborty S, Carnazza M, Jarboe T, DeSouza N, Li XM, Moscatello A, Geliebter J, Tiwari RK.
    Adv Exp Med Biol; 2021 Jul 05; 1350():33-66. PubMed ID: 34888843
    [Abstract] [Full Text] [Related]

  • 8. Integrated analysis of novel macrophage related signature in anaplastic thyroid cancer.
    Luo Y, Yang YC, Ma B, Xu WB, Liao T, Wang Y.
    Endocrine; 2022 Dec 05; 78(3):517-530. PubMed ID: 36070052
    [Abstract] [Full Text] [Related]

  • 9. The oncolytic virus dl922-947 reduces IL-8/CXCL8 and MCP-1/CCL2 expression and impairs angiogenesis and macrophage infiltration in anaplastic thyroid carcinoma.
    Passaro C, Borriello F, Vastolo V, Di Somma S, Scamardella E, Gigantino V, Franco R, Marone G, Portella G.
    Oncotarget; 2016 Jan 12; 7(2):1500-15. PubMed ID: 26625205
    [Abstract] [Full Text] [Related]

  • 10. Identification of novel characteristic biomarkers and immune infiltration profile for the anaplastic thyroid cancer via machine learning algorithms.
    Li C, Dong X, Yuan Q, Xu G, Di Z, Yang Y, Hou J, Zheng L, Chen W, Wu G.
    J Endocrinol Invest; 2023 Aug 12; 46(8):1633-1650. PubMed ID: 36725810
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. CSPG4 Is a Potential Therapeutic Target in Anaplastic Thyroid Cancer.
    Egan CE, Stefanova D, Ahmed A, Raja VJ, Thiesmeyer JW, Chen KJ, Greenberg JA, Zhang T, He B, Finnerty BM, Zarnegar R, Jin MM, Scognamiglio T, Dephoure N, Fahey T, Min IM.
    Thyroid; 2021 Oct 12; 31(10):1481-1493. PubMed ID: 34078123
    [Abstract] [Full Text] [Related]

  • 15. TIM3 Expression in Anaplastic-Thyroid-Cancer-Infiltrating Macrophages: An Emerging Immunotherapeutic Target.
    Palacios LM, Peyret V, Viano ME, Geysels RC, Chocobar YA, Volpini X, Pellizas CG, Nicola JP, Motran CC, Rodriguez-Galan MC, Fozzatti L.
    Biology (Basel); 2022 Nov 03; 11(11):. PubMed ID: 36358310
    [Abstract] [Full Text] [Related]

  • 16. Dissecting Anaplastic Thyroid Carcinoma: A Comprehensive Clinical, Histologic, Immunophenotypic, and Molecular Study of 360 Cases.
    Xu B, Fuchs T, Dogan S, Landa I, Katabi N, Fagin JA, Tuttle RM, Sherman E, Gill AJ, Ghossein R.
    Thyroid; 2020 Oct 03; 30(10):1505-1517. PubMed ID: 32284020
    [Abstract] [Full Text] [Related]

  • 17. Anti-PD-1/PD-L1 therapy augments lenvatinib's efficacy by favorably altering the immune microenvironment of murine anaplastic thyroid cancer.
    Gunda V, Gigliotti B, Ashry T, Ndishabandi D, McCarthy M, Zhou Z, Amin S, Lee KE, Stork T, Wirth L, Freeman GJ, Alessandrini A, Parangi S.
    Int J Cancer; 2019 May 01; 144(9):2266-2278. PubMed ID: 30515783
    [Abstract] [Full Text] [Related]

  • 18. Identification of a novel immune checkpoint molecule V-set immunoglobulin domain-containing 4 that leads to impaired immunity infiltration in pancreatic ductal adenocarcinoma.
    Jiang Y, Han L, Yang J, Yang M, Zhang J, Xue M, Zhu Y, Xiong C, Shi M, Zhao S, Shen B, Xu Z, Jiang L, Chen H.
    Cancer Immunol Immunother; 2023 Aug 01; 72(8):2701-2716. PubMed ID: 37097516
    [Abstract] [Full Text] [Related]

  • 19. Inflammatory Components of the Thyroid Cancer Microenvironment: An Avenue for Identification of Novel Biomarkers.
    Jarboe T, Tuli NY, Chakraborty S, Maniyar RR, DeSouza N, Xiu-Min Li, Moscatello A, Geliebter J, Tiwari RK.
    Adv Exp Med Biol; 2021 Aug 01; 1350():1-31. PubMed ID: 34888842
    [Abstract] [Full Text] [Related]

  • 20. Targeted next-generation sequencing for TP53, RAS, BRAF, ALK and NF1 mutations in anaplastic thyroid cancer.
    Latteyer S, Tiedje V, König K, Ting S, Heukamp LC, Meder L, Schmid KW, Führer D, Moeller LC.
    Endocrine; 2016 Dec 01; 54(3):733-741. PubMed ID: 27696251
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.